Wealth Enhancement Advisory Services
MTNB icon

Wealth Enhancement Advisory Services’s Matinas BioPharma MTNB Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,387
Closed -$18.9K – 2878
2024
Q2 		$18.9K Hold
2,387
– – ﹤0.01% 2493
2024
Q1 		$32.3K Hold
2,387
– – ﹤0.01% 2365
2023
Q4 		$25.8K Buy
+2,387
New +$26.9K ﹤0.01% 2244

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Wealth Enhancement Advisory Services's MTNB Position: Q3 2024 in Review

Wealth Enhancement Advisory Services sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 2,387 shares — an estimated $18.9K sold.

Wealth Enhancement Advisory Services first reported a position in MTNB in Q4 2023 and held it in 3 quarters. The position peaked at $32.3K in Q1 2024. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Wealth Enhancement Advisory Services reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 2,387 Matinas BioPharma shares in Q3 2024, an estimated $18.9K.
  • Wealth Enhancement Advisory Services first reported a position in Matinas BioPharma in Q4 2023 and held it in 3 quarters.
  • Wealth Enhancement Advisory Services's Matinas BioPharma position peaked at $32.3K in Q1 2024.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2024, filed 24 Oct 2024.